Clinical trials: CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction
CLDN18.2-Positive Gastric Cancer, CLDN18.2-Positive Gastroesophageal Junction Adenocarcinoma
Zolbetuximab, Durvalumab, and FLOT Combination Neoadjuvant Chemotherapy for CLDN18.2-Positive Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Claudin 18.2 (CLDN18.2) is a molecular target expressed in a subset of gastric and gastroesophageal junction (GEJ) adenocarcinomas.
- Trial name
- Zodiac-Neo (NCT07872722)
- Testing
- Zolbetuximab, Durvalumab, FLOT (5-fluorouracil, leucovorin, oxaliplatin, and docetaxel)
- Where
- 4 sites in Japan
- Volunteers
- 29 people
- Sponsor
- National Cancer Center, Japan
CLDN18.2 Positive, Gastric/Gastroesophageal Junction Adenocarcinoma
IBI343 in Combination Therapy for Advanced Malignant Solid Tumors
A Phase II study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of IBI343 in combination therapy for patients with advanced malignant solid tumors.To evaluate the efficacy and safety of IBI343 in combination…
- Conditions
- CLDN18.2 Positive, Gastric/Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07483554
- Testing
- IBI343,Gemcitabine, Albumin-bound Paclitaxel
- Where
- China
- Volunteers
- 389 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
CLDN18.2 Positive, Primary Gastric Adenocarcinoma
IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
This study is a prospective, randomized, open, multicenter phase II clinical trial. It plans to enroll 70 participants with locally advanced gastric and gastroesophageal junction adenocarcinoma (G/GEJ AC) who are assessed as…
- Conditions
- CLDN18.2 Positive, Primary Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT07483567
- Testing
- IBI343,sintilimab,oxaliplatin,S-1, sintilimab,oxaliplatin,S-1
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, CLDN18.2-positive Adenocarcinoma of Esophagus
Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer
The purpose of the trial is to assess the therapeutic effects and the safety profile of IMAB362 combined with EOX (epirubicin, oxaliplatin, capecitabine) as first-line treatment for patients with advanced adenocarcinoma of the…
- Conditions
- CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, CLDN18.2-positive Adenocarcinoma of Esophagus, CLDN18.2-positive Gastric Adenocarcinoma
- Trial name
- FAST (NCT01630083)
- Testing
- epirubicin, oxaliplatin, capecitabine
- Where
- 48 sites in Bulgaria, Czechia and 4 more
- Volunteers
- 252 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Gastric Cancer, HER2 + Gastric Cancer
Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping
This study is a prospective, umbrella-design, Phase II clinical trial. Eligible participants with advanced or metastatic gastric cancer who are treatment-naïve for advanced-stage systemic therapy will undergo biomarker profiling…
- Conditions
- Gastric Cancer, HER2 + Gastric Cancer, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, PD-L1 Positive
- Trial name
- NCT06881017
- Testing
- Trastuzumab, Adebrelimab, Apatinib
- Volunteers
- 140 people
- Sponsor
- China Medical University, China
CLDN18.2-positive Gastric Adenocarcinoma, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction
Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer
The purpose of the trial is to assess the immunological effects and their kinetics, the safety and activity of IMAB362 plus Zoledronic acid with/without low to intermediate doses of Interleukin-2 in subjects with advanced…
- Conditions
- CLDN18.2-positive Gastric Adenocarcinoma, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, CLDN18.2-positive Adenocarcinoma of Esophagus
- Trial name
- PILOT (NCT01671774)
- Testing
- IMAB362, Zoledronic acid, Interleukin-2 (1 million IU)
- Where
- 9 sites in Germany, Latvia
- Volunteers
- 29 people
- Sponsor
- Astellas Pharma Global Development, Inc.